Co-treatment of tuberculosis and HIV: Pharmacologic considerations

Ethel D. Weld, Alice K. Pau, Gary Maartens, Kelly E. Dooley

Research output: Chapter in Book/Report/Conference proceedingChapter


Having HIV and TB worsens the impact of both. The treatment of HIV-TB coinfection is beset by challenges, including drug-drug-interactions, coincident toxicities, and the occurrence of the immune reconstitution inflammatory syndrome. These challenges can be overcome with careful attention to evidence-guided practice and clinical pharmacological aspects of co-treatment. There is a clear mortality benefit to treating both infections; the relative timing of initiation of both treatments will be discussed. This chapter will address pharmacologic considerations in the co-treatment of HIV-related latent or active TB of all sensitivity patterns (drug sensitive and multidrug resistant (MDR). The discussion will identify existing gaps in the evidence and include current recommendations for HIV-TB treatment in special populations, including pregnant and lactating women and children.

Original languageEnglish (US)
Title of host publicationHIV and Tuberculosis
Subtitle of host publicationA Formidable Alliance
PublisherSpringer International Publishing
Number of pages29
ISBN (Electronic)9783030291082
ISBN (Print)9783030291075
StatePublished - Jan 1 2019


  • Co-management
  • Drug-drug-interactions
  • HIV
  • Pharmacology
  • Tuberculosis

ASJC Scopus subject areas

  • Medicine(all)
  • Immunology and Microbiology(all)


Dive into the research topics of 'Co-treatment of tuberculosis and HIV: Pharmacologic considerations'. Together they form a unique fingerprint.

Cite this